Leo Pharma announces Health Canada approval of Anzupgo for treatment of moderate to severe chronic hand eczema

26 August 2025 - Approval was based on results from the DELTA 1 and 2 trials, which evaluated the safety and ...

Read more →

Repatha now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C

25 August 2025 - Amgen today announced that the US FDA has broadened the approved use of Repatha (evolocumab) to include ...

Read more →

European Commission authorises twice yearly Yeytuo (lenacapavir) for HIV prevention

26 August 2025 - Accelerated EC decision comes after US FDA approval in June. ...

Read more →

Enhertu approved in Japan as first HER2 directed medicine for patients with HER2 low or HER2 ultra-low metastatic breast cancer following at least one endocrine therapy

25 August 2025 - Based on DESTINY-Breast06 phase 3 trial results that showed Enhertu demonstrated superiority versus chemotherapy with a ...

Read more →

Datroway approved in China for patients with previously treated metastatic HR positive, HER2 negative breast cancer

25 August 2025 - First approval in China for Daiichi Sankyo and AstraZeneca’s Datroway based on TROPIONBreast01 results showing 37% reduction ...

Read more →

Moderna receives Health Canada approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

22 August 2025 - All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone. ...

Read more →

Health Canada approves Roche’s Columvi (glofitamab) as the first bi-specific antibody in Canada for relapsed or refractory diffuse large B-cell lymphoma after initial therapy

21 August 2025 -  Approval is based on Phase 3 STARGLO study where Columvi in combination with chemotherapy showed a ...

Read more →

European Commission approves tablet formulation of BeOne Medicines’ Brukinsa for all approved indications

21 August 2025 - Tablets will advance treatment simplicity and convenience to meet patient needs across Europe. ...

Read more →

Bewildering PBAC decision a missed opportunity to ensure Australian cancer patients not left behind

23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the ...

Read more →

Recommendations made the PBAC – July 2025

22 August 2025 - The recommendations from the July 2025 PBAC meeting are now available. ...

Read more →

Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer

23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...

Read more →

Injectable form of Ocrevus for relapsing remitting multiple sclerosis recommended for PBS listing

22 August 2025 - This new form of ocrelizumab is given as an injection under the skin (subcutaneously), takes a much ...

Read more →

New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year

23 August 2025 - New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k/year. ...

Read more →

Health Canada grants marketing authorisation for an additional indication of Bayer's Nubeqa (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer

21 August 2025 - Bayer is pleased to announce that Health Canada has granted marketing authorisation for its oral androgen receptor ...

Read more →

Dawnzera (donidalorsen) approved in the US as first and only RNA targeted prophylactic treatment for hereditary angioedema

21 August 2025 - Offers longest dosing option for hereditary angioedema, with dosing every 4 or 8 weeks. ...

Read more →